97 results
Page 2 of 5
DEFA14A
xgjyrqvm
12 Jan 21
Additional proxy soliciting materials
5:15pm
DEFA14A
fmujzjkb9k9n
23 Dec 20
Additional proxy soliciting materials
4:52pm
DEFA14A
egcvcqlk
21 Dec 20
Additional proxy soliciting materials
9:17pm
DEFA14A
EX-2.1
i47yik
21 Dec 20
Additional proxy soliciting materials
9:17pm
8-K
553soj8ed
21 Dec 20
Entry into a Material Definitive Agreement
9:15pm
8-K
EX-2.1
eup9l6nyqj1o8rgf
21 Dec 20
Entry into a Material Definitive Agreement
9:15pm
DEFA14A
ea0en7t4i95 rjo6e
21 Dec 20
Additional proxy soliciting materials
5:21pm
8-K
EX-99.1
ceg59 7qu
7 Dec 20
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
4:53pm
8-K
EX-99.2
inac17 isn
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
S-3ASR
EX-4.6
7skriex49wnozr dka
30 Apr 20
Automatic shelf registration
4:19pm
S-3ASR
EX-4.4
y108v54okbgk9m 21
30 Apr 20
Automatic shelf registration
4:19pm
S-3ASR
EX-4.5
ejjxufw3w
30 Apr 20
Automatic shelf registration
4:19pm
S-3ASR
tpv8rzop qu6ksw5yg7h
30 Apr 20
Automatic shelf registration
4:19pm
S-3ASR
EX-4.7
wlgl9kxucy9dmhbnzce2
30 Apr 20
Automatic shelf registration
4:19pm
8-K
EX-99.1
logssi 48
30 Apr 20
Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations andCOVID-19 Response
7:19am
8-K
EX-99.1
l7jrs8xekc
13 Jan 20
Regulation FD Disclosure
4:32pm
8-K
EX-99.2
ow6wv2ag
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm